Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Antiangiogenic tumour therapy: will it work?

H G Augustin1

  • 1Department of Gynaecology and Obstetrics, University of Göttingen Medical School, Germany.

Trends in Pharmacological Sciences
|July 17, 1998
PubMed
Summary

Inhibiting angiogenesis, the formation of new blood vessels, offers a promising strategy for novel cancer therapies. Research shows anti-angiogenic treatments can prevent tumor metastasis and shrink tumors.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Angiopoietin-2 mediates thrombin-induced monocyte adhesion and endothelial permeability.

Journal of thrombosis and haemostasis : JTH·2016
Same author

Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy.

British journal of cancer·2010
Same author

Distinct activities of Bartonella henselae type IV secretion effector proteins modulate capillary-like sprout formation.

Cellular microbiology·2009
Same author

Modulation of in vitro angiogenesis in a three-dimensional spheroidal coculture model for bone tissue engineering.

Tissue engineering·2004
Same author

Translating angiogenesis research into the clinic: the challenges ahead.

The British journal of radiology·2004
Same author

Quantitating angiogenesis and assessing the causal relationship between angiogenesis and tumorigenesis: problems and progress.

Annals of hematology·2003

Area of Science:

  • Oncology
  • Vascular Biology
  • Biomedical Research

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth and metastasis.
  • Inhibiting angiogenesis is a promising strategy for novel antineoplastic therapies.
  • Gene inactivation experiments in mice have identified key molecules regulating embryonic angiogenesis.

Purpose of the Study:

  • To review the differences between developmental, physiological, and pathological angiogenesis.
  • To summarize experimental approaches for anti-angiogenic therapies.
  • To discuss critical issues in translating anti-angiogenic strategies into clinical practice.

Main Methods:

  • Review of existing literature on angiogenesis and anti-angiogenic therapies.
  • Analysis of gene inactivation experiments in mice.
  • Examination of animal and human tumor studies.

Main Results:

  • Animal studies demonstrate that angiogenesis inhibitors can prevent metastasis and reduce experimental tumors.
  • Differences exist between angiogenesis in development, adult physiology, and pathological conditions.
  • Key vascular endothelium-related molecules are rate-limiting for embryonic angiogenesis.

Conclusions:

  • Inhibiting angiogenesis is a viable strategy for developing new cancer treatments.
  • Understanding different types of angiogenesis is crucial for therapeutic development.
  • Clinical translation of anti-angiogenic therapies requires careful consideration of critical issues.

Related Experiment Videos